Comparative Evaluation of Amlodipine Besylate Generic Tablet and Capsule Brands in Riyadh, Saudi Arabia

IF 1 4区 医学 Q4 PHARMACOLOGY & PHARMACY Dissolution Technologies Pub Date : 2022-01-01 DOI:10.14227/dt290422pgc2
Doaa R. Adam, Nuran Al Rayes, Raghad Fatoum, Ghosoun M. Arafeh, T. Adam, A. Kola-Mustapha
{"title":"Comparative Evaluation of Amlodipine Besylate Generic Tablet and Capsule Brands in Riyadh, Saudi Arabia","authors":"Doaa R. Adam, Nuran Al Rayes, Raghad Fatoum, Ghosoun M. Arafeh, T. Adam, A. Kola-Mustapha","doi":"10.14227/dt290422pgc2","DOIUrl":null,"url":null,"abstract":"The objective of this study was to evaluate the physicochemical quality control parameters and pharmaceutical equivalence of amlodipine besylate generic tablets and capsules with the innovator brands (Norvasc and Amlor, respectively) available in Riyadh, Saudi Arabia. Five brands of amlodipine besylate tablets and capsules (5 mg) were compared via quality control tests according to the United States Pharmacopoeia (i.e., hardness, thickness, diameter, weight variation, uniformity of dosage content, friability, disintegration, dissolution by ultraviolet spectrophotometry, and Fourier-transform infrared spectroscopy (FTIR)). All selected brands were found to comply with USP-NF specifications concerning weight variation, hardness, friability, disintegration time, FTIR, and drug content analysis. The dissolution profiles for all products satisfied the USP-NF specifications. Regarding, model-dependent data, all the tested brands followed the Higuchi model of release. Using the model-independent approach (i.e., similarity factor analysis), all products were considered similar except for one generic product (ABC-3). All brands had no significant difference in mean dissolution efficiency compared to the innovator, except ABC-3.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"1 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dissolution Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14227/dt290422pgc2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The objective of this study was to evaluate the physicochemical quality control parameters and pharmaceutical equivalence of amlodipine besylate generic tablets and capsules with the innovator brands (Norvasc and Amlor, respectively) available in Riyadh, Saudi Arabia. Five brands of amlodipine besylate tablets and capsules (5 mg) were compared via quality control tests according to the United States Pharmacopoeia (i.e., hardness, thickness, diameter, weight variation, uniformity of dosage content, friability, disintegration, dissolution by ultraviolet spectrophotometry, and Fourier-transform infrared spectroscopy (FTIR)). All selected brands were found to comply with USP-NF specifications concerning weight variation, hardness, friability, disintegration time, FTIR, and drug content analysis. The dissolution profiles for all products satisfied the USP-NF specifications. Regarding, model-dependent data, all the tested brands followed the Higuchi model of release. Using the model-independent approach (i.e., similarity factor analysis), all products were considered similar except for one generic product (ABC-3). All brands had no significant difference in mean dissolution efficiency compared to the innovator, except ABC-3.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
沙特利雅得市苯磺酸氨氯地平仿制片与胶囊品牌比较评价
本研究的目的是评价在沙特阿拉伯利雅得上市的创新品牌(分别为Norvasc和Amlor)苯磺酸氨氯地平仿制片和胶囊的理化质量控制参数和药物等效性。采用紫外分光光度法、红外光谱法(FTIR)对5个品牌的苯磺酸氨氯地平片剂和胶囊(5mg)进行了硬度、厚度、直径、重量变化、剂量含量均匀性、脆性、崩解度、溶出度等质量控制试验。所有选定的品牌都符合USP-NF关于重量变化,硬度,脆性,崩解时间,FTIR和药物含量分析的规范。所有产品的溶出度符合USP-NF标准。在车型相关数据方面,所有被测品牌均遵循Higuchi发布模型。使用模型独立方法(即相似因子分析),除了一个通用产品(ABC-3)外,所有产品都被认为是相似的。除ABC-3外,所有品牌的平均溶出效率与创新者相比均无显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dissolution Technologies
Dissolution Technologies 医学-药学
CiteScore
1.20
自引率
33.30%
发文量
14
审稿时长
3 months
期刊介绍: Dissolution Technologies is a peer reviewed quarterly publication reporting ongoing, useful information on dissolution testing of pharmaceuticals. It provides an international forum for dissolution analysts to receive and exchange information on various dissolution topics. Dissolution Technologies welcomes submissions related to dissolution, in vitro release, and disintegration testing. These topics should be the major focus of the article. Do not submit articles where the focus is formulation development with dissolution testing as one of many tests.
期刊最新文献
Steady-state burning plasma: a new stage in the development of magnetic confinement fusion energy. Investigating the Influence of HPMC K4M and Eudragit L 100-55 on Guanfacine-Loaded Extended-Release Tablets Questions and Answers February 2023 Effect of Mannitol Particle Size on Melatonin Dissolution and Tablet Properties using a Quality by Design Framework Physicochemical Quality and In Vitro Bioequivalence of Amoxicillin Capsules Marketed in Burkina Faso, Africa
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1